

## Original Research Article

**A retrospective analysis of data collected over 05 years for prevalence of *Helicobacter pylori* infestation in symptomatic patients from Jammu and Kashmir****Shoket Mehmood Chowdry<sup>1</sup>, Yasmeen Kousar<sup>2</sup>, Ab. Hamid Wani<sup>3</sup>,  
Javid Iqbal<sup>4\*</sup>**<sup>1</sup>*Assistant Professor, Department of Gastroenterology, Government Medical College Jammu, Jammu and Kashmir, India*<sup>2</sup>*Medical Officer, Government Medical College Jammu, Jammu and Kashmir, India*<sup>3</sup>*Assistant Professor, Department of Surgery, Government Medical College Jammu, Jammu and Kashmir, India*<sup>4</sup>*Assistant Professor, Department of Surgery, Government Medical College Jammu, Jammu and Kashmir, India***Received: 08-01-2021 / Revised: 17-03-2021/ Accepted: 26-04-2021****Abstract**

**Introduction:** Infection with *H. pylori* is common. About two-third of the population in the world carry *H. pylori* in their bodies. The infection is acquired in the childhood and persists despite of local and systemic immune response. **Materials and Methods:** This was a prospective observational study done on 1000 patients at a tertiary health care hospital in Jammu, India, over a period of 04 years (March 2016 to March 2020). Written and informed consent regarding the purpose, procedures, and risks was obtained from all patients. Data were collected by conducting personal interview and doing a complete physical examination of the participants of the study. All patients underwent basic investigations as per symptoms and comorbidities. UGIE was performed on all the study participants using a video gastroscope. Gross features of the upper GI tract were noted and biopsies were obtained from the stomach (antrum, body, and fundus), and second part of the duodenum. One antral and one corpus biopsy sample each were used for rapid urease test (RUT). **Results:** A total of 1000 patients underwent UGIE for different set of complaints. Most common complaint in this study group was epigastric pain (43%) followed by dyspepsia (33.2%) and 80.23% and 78.61% patients were positive for *H. pylori* on RUT. On UGI endoscopy duodenal ulcer was seen in 430 patients and among them 85.34% were *H. pylori* positive on RUT, gastric ulcer was seen in 240 patients and among them 73.33% were *H. pylori* positive. Most common comorbidity was hypertension in the study group and among these patients 138(88.46%) were *H. pylori* positive, 2<sup>nd</sup> common comorbidity was Diabetes mellitus and among them 133(91.86%) were *H. pylori* positive. Overall prevalence of *H. pylori* manifestation in study group was seen in 78.5% patients. **Conclusion:** Among all symptomatic patients enrolled in this study the most symptom was epigastric pain followed by dyspepsia and most common comorbidities in the study group were HTN and Diabetes mellitus. Rapid urease test was performed on UGI endoscopic biopsy specimen for *H. pylori* infestation and 78.5% patients were found to be positive.

**Keywords:** *H. pylori*, Rapid urease test, Dyspepsia, Biopsy, Duodenal ulcer.

This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

**Introduction**

Infection with *Helicobacter pylori* (*H. pylori*) infection is common. About two-third of the population in the world carry HP in their bodies. The infection is acquired in the childhood and persists despite of local and systemic immune response [1, 2]. Majority of the infections remain asymptomatic and only 10- 20% progress to clinical disease [3]. *H. pylori* is a gram negative bacterium. It colonizes the mucosal lining of the human digestive tract. It has special affinity for stomach and duodenum [1]. Right from its discovery by Warren and Marshall in the early eighties; research on *H. pylori* is voluminous [4, 5]. It is considered to be one of the most common chronic bacterial infections which affect almost two thirds of the worldwide population [6]. The transmission of this bacteria is from person to person and through contaminated water. It causes inflammation in the gut especially in the stomach and duodenum [7]. Most of these inflammatory changes are silent and clinical

manifestations occur in around one fifth of the patients after a long latent period [6]. *H. pylori* causes chronic active gastritis as a rule in almost all the patients. Studies have shown that this infection has a role in causing peptic ulcer disease (PUD), atrophic gastritis, gastric neoplasm, and "mucosa-associated lymphoid tissue (MALT)" lymphoma [7, 9]. The infection has also been implicated to cause iron deficiency anemia; idiopathic thrombocytopenia and vitamin B12 deficiency [10, 11]. The guidelines of the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) state that endoscopic biopsy is an important component for the initial detection of *H. pylori* infection [12].

**Materials and Methods**

This was a prospective observational study done at a tertiary health care hospital in Jammu, India, over a period of 04 years (March 2016 to March 2020). Written and informed consent regarding the purpose, procedures, and risks was obtained from all patients. Data were collected by conducting personal interview and doing a complete physical examination of the participants of the study. A structured pro forma was used and filled after interviewing and

\*Correspondence

**Dr. Javid Iqbal**

Assistant Professor, Department of Surgery, Government Medical College Jammu, Jammu and Kashmir, India

E-mail: [javidiqbal123@gmail.com](mailto:javidiqbal123@gmail.com)

examining the patient. The following information was collected for all the participants: age, gender, symptoms and their duration, comorbidities and their durations, any treatment patient has received. All patients underwent basic investigations as per symptoms and comorbidities. Patients having DM II underwent fasting and postprandial blood sugar levels, hemoglobin A1c (HbA1c) levels, All patients having pain abdomen and fatty dyspepsia also underwent USG Abdomen. UGIE was performed on all the study participants using a video gastroscope. Gross features of the upper GI tract were noted and biopsies were obtained from the stomach (antrum, body, and fundus), and second part of the duodenum. One

antral and one corpus biopsy sample each were used for rapid urease test (RUT) (for high yield). All the biopsy samples were also sent for histopathological examination (HPE). Commercially available RUT kit, manufactured by Halifax Research Laboratory, Kolkata, under the trade name of Pylo Dry, was used.

### Results

A total of 1000 patients underwent UGIE for different set of complaints.

**Table 1: Correlation of symptoms with *Helicobacter pylori* infection**

Symptoms	No. of patients %	H Pylori positive %	H Pylori negative %
Epigastric pain	430 (43%)	345 (34.5%)	85 (8.5%)
Dyspepsia	332 (33.2%)	261 (26.1%)	71 (7.1%)
Epigastric fullness	101(10.1%)	73 (7.3%)	28 (2.8%)
Loss of appetite	40 (4%)	30 (3.0%)	10 (1.0%)
Persistent vomiting	32 (3.2%)	23 (2.3%)	9 (0.9%)
Anemia	27 (2.7%)	21 (2.1%)	6 (0.6%)
Upper GI Bleed	18 (1.8%)	15 (1.5%)	3 (0.3%)
Loss of weight	14 (1.4%)	12 (1.2%)	2 (0.2%)
Melena	6 (0.6%)	5 (0.5%)	1 (0.1%)
	1000 (100%)	785(78.5%)	215 (21.5%)

Most common symptom in our study group was epigastric pain in 430 patients and among these 345 (34.5%) were H Pylori positive and 2<sup>nd</sup> commonest symptom was dyspepsia in 332 patients and among these 261 (26.1%) were H Pylori positive these symptoms

were followed by epigastric fullness, loss of appetite, vomiting, anemia and upper GI Bleed, weight loss and melena as shown in table 1.

**Table 2: Correlation of endoscopic abnormalities with *Helicobacter pylori* infection**

Endoscopic findings	H Pylori positive %	H Pylori negative %	Total
Duodenal ulcer	367 (36.7%)	63 (6.3%)	430
Gastric ulcer	176 (17.6%)	64 (6.4%)	240
Chronic gastritis	154 (15.4%)	52 (5.2%)	206
NUD	88 (8.8%)	36 (3.6%)	124
	785(78.5%)	215 (21.5%)	1000 (100%)

Duodenal ulcer was seen in 430 patients and among them 367(36.7%) were H pylori positive on RUT, gastric ulcer was seen in 240 patients and among them 176(17.6%) were H pylori positive, in

206 patients there was chronic gastritis and 154(15.4%) patients were H pylori positive and NUD was seen in 124 patients and among them 88(8.8%) were H pylori positive.

**Table 3: Correlation of comorbidities with *Helicobacter pylori* infection**

Comorbidities	No. of patients	H Pylori positive %	H Pylori negative %
Hypertension	156	138 (88.46%)	18 (11.5%)
Diabetes mellitus	138	133 (96.37%)	5 (3.62%)
Hypothyroidism	86	79 (91.86%)	7 (8.13%)
Hyperthyroidism	13	9 (69.23%)	4 (30.76%)
Portal HTN	9	3 (33.33%)	6 (66.66%)
CRF	4	4 (100%)	0 (0%)

Most common comorbidity was hypertension in the study group and among these patients 138(88.46%) were H pylori positive, 2<sup>nd</sup> common comorbidity was Diabetes mellitus and among them 133(91.86%) were H pylori positive and 04 patients had CRPF and all of them were H pylori positive.

### Discussion

The occurrence of H. pylori transmission varies from age, race, ethnicity and geographic area. The rate of transmission of H. pylori in developing countries is comparatively high as compared to developed nations. H. pylori bacterium has infected approximately 50 percent of the total population [6]. The frequency of H. pylori diseases is reducing over the last decade in many countries but still its intensity is high in some under developed countries. The decline of H. pylori is due to changes in the epidemiology of the bacterium

which further cause changes in the epidemiology of peptic ulcer, gastro esophageal reflux disease (GERD) and gastric cancer [13, 14]. Around 70% children of under developed countries may be affected by H. pylori infection. The cause of infection in children is contact with bacteria. A child may contact with the bacteria by not eating cleaned and properly cooked food, by drinks water which was contaminated with infected bacteria and by not washing hands properly after going to bathroom [15]. The rate of H. pylori infection is lower in developed nations such as Australia, North America and Western Europe whereas GERD ratio is higher over there [16-18]. In contrast, the frequency of H. pylori diseases is high in developing countries such as Europe, Africa, India, China and South America while GERD frequency is lower in them [19-22]. The rate of H. pylori infection can be reduced by improving personal hygienic and

sanitary infrastructure. There are several important steps for decreasing the prevalence of *H. pylori* infection i.e. washing hands thoroughly, eating food that is clean and properly cooked, by drinking clean water, by quitting smoking and reducing alcohol intake [23]. Epidemiological studies were done in different parts of Asia for *H. pylori* infection. Seroprevalence rate for *H. pylori* was high in Bangladesh and India. Study done by Ahmed et al. have shown highest prevalence rates of 90% among the asymptomatic individuals [24]. Recently some studies based on CLO test shows it is 67% which indicate decline in prevalence of infection. Moreover, the overall *H. pylori* prevalence in other Asian countries including India (79% by ELISA), Pakistan (84% by PCR), and Japan (41% by measuring urinary levels of anti-*H. pylori* antibody) was also reported high. In Europe (<40%) and the United States (<40%), a significantly lower prevalence rate of *H. pylori* was observed. A study of adults in Ontario, Canada, found that the overall seroprevalence was 23.1% that was higher in men (29.4%) than women (14.9%) [25]. In this study we looked for prevalence of *H. pylori* infection only in symptomatic patients, the prevalence of disease in study group was 78.5% in our patients by using RUT and the patients having Diabetes mellitus and CRF had very high prevalence of disease. The prevalence of *H. pylori* infection in our study was high as compared to a study conducted by Ahmed MM et al [26] for patients having dyspepsia, those underwent UBT where 23% patients were found positive for *H. pylori* infection. Another study conducted by Habib AM et al [27] in 2016 in Chittagong has shown a decrease in the prevalence of *H. pylori* in the older age groups. It was observed that *H. pylori* prevalence was higher in patients under the age of 30 years (78.3%) than in patients with ages between 30 and 40 years and over 40 years (63.3%). But the overall prevalence was 49% by PCR and 54% by CLO. The prevalence of disease in our study was also higher than this study when we used RUT for diagnosis of *H. pylori* infection in our study group. In a study conducted by Dutta et al among men, *H. pylori* was present in 45.7% while the frequency of infection in women was lower at 33.2%. In the 15-30 years age group, the frequency of infection was 42.6% while it was 48.3% in the 31-50 years group and 34.9% in the above 50 years group [28]. Kukreja et al [29] conducted a study in Gujarat by using RUT and found prevalence rate of *H. pylori* infection was 24.19 %. More than half (53%) of the infected patients had complained of persistent burning abdominal pain. Prevalence rate was found highest in the patients suffering from peptic ulcer disease (66.6%). Rajesh kumar et al [30] enrolled 265 symptomatic patients of acid peptic disease, out of which 92 patients were found *H. pylori* positive (by biopsy urease test and histopathological test) giving a prevalence of 34.71%. Among *H. pylori* positive patients, 64.13% were males and 35.86% were females. In a study by Agarwal et al [31], in a North Indian population they found total 41 (76%) patients out of 54, positive for *H. pylori* by RUT. By serology, we found 81% of patients positive. Collectively, total 85% of patients were found to be positive for *H. pylori* and 15 patients were negative. The prevalence of *H. pylori* infection was lesser in our study group as compared to this study population.

### Conclusion

Among all symptomatic patients enrolled in this study the most symptom was epigastric pain followed by dyspepsia and most common comorbidities in the study group were HTN and Diabetes mellitus. Rapid urease test was performed on UGI endoscopic biopsy specimen for *H. pylori* infestation and 78.5% patients were found to be positive.

### References

1. Suerbaum S, Michetti P. *Helicobacter pylori* infection. *N Engl J Med* 2002; 347:1175-1186.
2. Lacy BE, Rosemore J. *Helicobacter pylori*: Ulcers and more: The beginning of an era. *J Nutr*. 2001; 131:2789S-2793S.

3. Perez-Perez G, Rothenbacher D, Brenner H. Epidemiology of *Helicobacter pylori* infection. *Helicobacter* 2004; 9(Suppl 1):1-6.
4. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet*. 1984; 1:1311-1315
5. Mitchell H, Katelaris P. Epidemiology, clinical impacts and current clinical management of *Helicobacter pylori* infection. *The Medical Journal of Australia*. 2016; 204(10):376-80.
6. Brown LM. *Helicobacter pylori*: epidemiology and routes of transmission. *Epidemiologic Reviews*. 2000; 22(2): 283-97.
7. Axon A., Forman D. *Helicobacter gastroenteritis*: a serious infectious disease. *BMJ*, 1997; 314:1430-1.
8. Go MF. Natural history and epidemiology of *Helicobacter pylori* infection. *Alimentary Pharmacology & Therapeutics*, 2002; 16:3-15.
9. Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of *Helicobacter pylori*: a multicentre cohort follow-up study of 420 patients in Japan. *Gut*. 2012; 61(4):507-13.
10. Nurgalieva ZZ, Malaty HM, Graham DY, Almuchambetova R, Machmudova A, Kapsultanova D et al. *Helicobacter pylori* infection in Kazakhstan: effect of water source and household hygiene. *The American Journal of Tropical Medicine and Hygiene*, 2002; 67(2):201-6.
11. Queiroz DM, Harris PR, Sanderson IR, Windle HJ, Walker MM, Rocha AM et al. Iron status and *Helicobacter pylori* infection in symptomatic children: an international multi-centered study. *PLoS One*, 2013; 8(7):e68833.
12. Jones NL, Koletzko S, Goodman K, Bontems P, Cad-ranel S, Casswall T, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of *Helicobacter pylori* in children and adolescents. *J Pediatr Gastroenterol Nutr* 2017; 64:991-1003.
13. Fuccio L, Eusebi LH, Bazzoli F. Gastric cancer, *Helicobacter pylori* infection and other risk factors. *World J of Gastrointest Oncol*. 2010;2(9):342.
14. Sonnenberg A. Historic changes of *Helicobacter pylori*-associated diseases. *Aliment. Pharmacol. Ther.* 2013; 38(4): 329-42.
15. Abadi ATB. Diagnosis of *Helicobacter pylori* using invasive and noninvasive approaches. *Hindawi J of Pathogens* 2018, 1-13p.
16. Talley N, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. *Gut*. 1998; 42(5):690-695.
17. Hoang TT, Bengtsson C, Phung DC, Sörberg M, Granström M. Seroprevalence of *Helicobacter pylori* infection in urban and rural Vietnam. *Clin Diagn Lab Immunol* 2005; 12(1):81-85
18. Nwokediuko S. Gastroesophageal reflux disease: a population based study. *Gastroent Res Pract*. 2009; 2(3):152.
19. Sitaraman R. Allergies, *Helicobacter pylori* and the continental enigmas. *Front Microbiol*. 2015; 6:578.
20. Reshetnikov OV, Häivä VM, Granberg C, Kurilovich SA, Babin VP. Seroprevalence of *Helicobacter pylori* infection in Siberia. *Helicobacter* 2001; 6(4):331-336.
21. Wong WM, Lai KC, Lam KF, Hui WM, Hu WH, Lam CL et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. *Aliment Pharmacol Ther.* 2003; 18(6): 595-604.
22. Shah SS, Bhatia SJ, Mistry FP. Epidemiology of dyspepsia in the general population in Mumbai. *Indian J Gastroenterol*. 2001; 20(3):103-106.
23. Yucel O. Prevention of *Helicobacter pylori* infection in childhood. *WJG* 2014; 20(30):10348.

24. Ahmad MM, Rahman M, Rumi AK, et al. Prevalence of Helicobacter pylori in asymptomatic population -a pilot serological study in Bangladesh. J Epidemiol. 1997; 7(4):251-4.
25. Farah N, Nancy K, Terrence S. Helicobacter pylori infection in Ontario: Prevalence and risk factors. Can J Gastroenterol. 2007; 21(8):501-506.
26. Ahmed MM, Saeed A, Masum A, Mohiuddin M, Rahman A. Declining Prevalence of Helicobacter Pylori Infection- A 13C Urea Breath Test (UBT) Based Study in Symptomatic Subjects in Dhaka, Bangladesh AKMMC J 2019; 10(2):121-124
27. Habib AM, Alam MJ, Rudra B, Quader MA, Al- Furkan M. Analysis of HP prevalence in Chittagong, Bangladesh, based on PCR and CLO test. Microbiol. 2016; 9:47-50
28. Datta AK, Reddi VD ET, Iyer VH, Unnikrishnan LS, Chacko A et al. Exploring current status of HP infection in different age group. Indian J. Gastroenterol. 2017; 36(6):509-513.
29. Kukreja AK, Pandya HB, Kumar S. Prevalence and risk factors of Helicobacter pylori infections in the patients suffering from acid-peptic disease at tertiary care center, Gujarat, India. Int J Adv Med. 2018;5:1250-5.
30. Kumar R, Bano G, Kapoor B, Sharma S, Gupta Y. Clinical Profile in H. Pylori Positive Patients in Jammu. Jk science. 2006;8(3): 148-150.
31. Agarwal PK, Badkur M, Agarwal R, Patel S. Prevalence of Helicobacter pylori infection in upper gastrointestinal tract disorders (dyspepsia) patients visiting outpatient department of a hospital of North India. J Family Med Prim Care. 2018;7:577-80.

**Conflict of Interest:** Nil

**Source of support:** Nil